Clinical Trial

A Study of SHR-2173 in Participants With Systemic Lupus Erythematosus

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is a randomized, double-blind, multi-center, placebo-controlled Phase II clinical trial to evaluate the efficacy and safety of SHR-2173 in adult participants with active Systemic Lupus Erythematosus (SLE), including a 4-week screening period, a 24-week core treatment period, a 24-week maintenance treatment period, and a 12-week safety follow-up period. Approximately 245 SLE patients will be included.
Protocol Amendment History 1 change
critical Recruitment opened 2026-05-12
Trial Details
NCT Number NCT07299422
Lead Sponsor Guangdong Hengrui Pharmaceutical Co., Ltd
Conditions Systemic Lupus Erythematosus
Enrollment 248 participants
Start Date 2026-04-03
Primary Completion 2028-03 (estimated)
Study Completion 2028-11 (estimated)
Updated on ClinicalTrials.gov 2026-05-11